NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf030 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Zoe K Bedrosian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS 66160, United States. Hauptthemen laut MEDLINE: NK Cell Lectin-Like Receptor Subfamily K, Killer Cells, Natural, Signal Transduction, Cytokines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Kansas Endowment Foundation, NCI NIH HHS, V Foundation for Cancer Research.
Abstract (Originalsprache)
Studies support a role for natural killer (NK) cells in cancer control, making these cells attractive for immunotherapy. One method being tested to make effective NK cells is the ex vivo activation with interleukin (IL)-12, IL-15, and IL-18. We demonstrate that this induces NKG2D ligands on NK cells. By engaging NKG2D, this NKG2D ligand expression eliminated the ability of both mouse and human NK cells to control tumor growth in vivo and in vitro, respectively. NKG2D-NKG2D ligand interaction between mouse NK cells reduced NK cell proliferation, CD25 and T-bet expression, and tumor necrosis factor and interferon γ release. NKG2D signaling induced between human NK cells similarly decreased interferon γ but did not affect T-bet or CD25 expression. These data demonstrate that NKG2D signaling can cross-tolerize cytokine signaling and suggest that eliminating this signaling could be beneficial in NK cell adoptive therapy. Further, these results highlight a need to better delineate effects downstream of NKG2D signaling in human, rather than mouse, NK cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS 66160, United States.
ORCID-Profile: Mary A Markiewicz
Förderung
- University of Kansas Endowment Foundation
- NCI NIH HHS
- V Foundation for Cancer Research
- NIGMS NIH HHS
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute Cancer Center
Zitieren
APA
Bedrosian, Z. K., Ruark, E. M., Sharma, N., Silverstein, R. B., Manning, A., Kohlsaat, L., & Markiewicz, M. A. (2025). NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf030
Vancouver
Bedrosian ZK, Ruark EM, Sharma N, Silverstein RB, Manning A, Kohlsaat L, et al. NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf030
BibTeX
@article{Bedrosian2025,
author = {Bedrosian, Zoe K and Ruark, Elizabeth M and Sharma, Neekun and Silverstein, Rachel B and Manning, Allison and Kohlsaat, Lauren and Markiewicz, Mary A},
title = {NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf030}
}
EUVIMED